Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.90 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957621 | 0.95 | SIGMAR1 (1.00) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| Oxalic Acid SCHEMBL957600 | 0.88 | SIGMAR1 (0.70) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| Oxalic Acid SCHEMBL955875 | 0.88 | SIGMAR1 (0.70) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| Oxalic Acid SCHEMBL4533958 | 0.85 | SIGMAR1 (0.65) | SIGMAR1TMEM97DRD2SLC18A3HRH3 | |
| SCHEMBL5170674 | 0.85 | SIGMAR1 (0.80) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| Oxalic Acid SCHEMBL955045 | 0.84 | SIGMAR1 (0.64) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| SCHEMBL8274349 | 0.84 | SIGMAR1 (0.80) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| Oxalic Acid SCHEMBL954732 | 0.83 | SIGMAR1 (0.64) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| SCHEMBL955900 | 0.82 | SIGMAR1 (0.77) | SIGMAR1TMEM97DRD2HTR1AHTR2A | |
| SCHEMBL954292 | 0.82 | SIGMAR1 (0.77) | SIGMAR1TMEM97DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394797-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-12 | — | — | US | claimed |
| EP-1781619-B1 | SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2011-08-17 | — | — | EP | claimed |
| US-7282499-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-16 | — | — | US | claimed |
| US-20070232585-A1 | Sigma Receptor Inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-04 | — | — | US | claimed |
| EP-1781619-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | claimed |
| EP-1634873-A1 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-15 | — | — | EP | claimed |
| US-20060047127-A1 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | US | claimed |
| WO-2006021463-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| US-8394797-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-12 | — | — | US | disclosed |
| US-7282499-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-16 | — | — | US | disclosed |
| US-20070232585-A1 | Sigma Receptor Inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-04 | — | — | US | disclosed |
| EP-1781619-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| EP-1634873-A1 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-15 | — | — | EP | disclosed |
| US-20060047127-A1 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | US | disclosed |
| WO-2006021463-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232585-A1 | Sigma Receptor Inhibitors | SIGMAR1, OPRK1, OPRL1 | OPRM1 6/4885SIGMAR1 1/4885TMEM97 5/4885 |
| US-20060047127-A1 | Sigma receptor inhibitors | SIGMAR1, OPRK1, OPRL1 | OPRM1 6/4885SIGMAR1 1/4885TMEM97 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.